Globalworld globe
United Kingdom
North America
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

ASX Announcement – Green Whistle receives regulatory approval in South Africa

Jul 4, 2014News

Medical Developments International Limited (ASX:MVP) has received approval from the Medicines Control Council (MCC) in South Africa to market and sell its inhaled analgesic product, ?Penthrox?? for pain relief from trauma and surgical procedures.

The approval gives MVP?s partner in South Africa, LINK Healthcare Pte Ltd (through its wholly owned subsidiary Equity Pharmaceuticals Pty Ltd), the right to start selling ?Penthrox? (marketed as ?Penthrop? in South Africa) effective immediately.? LINK Healthcare estimates the size of the prescription only analgesic market in South Africa is $90 million.

The approval in South Africa opens the regulatory pathway for approvals to sell Penthrox in Namibia, Botswana, Lesotho, Swaziland, Angola, Malawi, Mozambique and Zambia.? LINK Healthcare advise the approval process in these countries will take less than 12 months because South African regulators have registered Penthrox for sale.? MVP CEO, Mr. John Sharman said ?this approval is a great opportunity for our company and could open the door to Africa?.

Mr. Sharman said ?this registration is the first indication we have received that the work done on our clinical trials in England for our regulatory dossier in that country, will enable our company to get approval to sell Penthrox in countries other than the EU where we are currently being assessed. ?MVP is in discussion with pharmaceutical companies in various countries in Europe and elsewhere and we are hopeful we can conclude a number of licensing and distribution agreements in the coming months.?

ASX Announcement – Penthrox approved in South Africa

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Appointment of Non-Executive Director – Mary Sontrop

    5 March 2021 ASX ANNOUNCE...

  • FY21 Half Year Report and Accounts

    26 February 2021 ASX ANNO...

  • MVP Completes $25m Placement

    14 December 2020 ASX ANNO...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me


Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: mdi@medicaldev.com
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: medinf@medicaldev.com

Email Newsletter

Sign up to our newsletter to receive MDI corporate, investor  & media news.